Back to top
more

Harvard Bioscience (HBIO)

(Real Time Quote from BATS)

$3.70 USD

3.70
23,423

-0.02 (-0.54%)

Updated Apr 24, 2024 02:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (35 out of 252)

Industry: Instruments - Scientific

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?

by Zacks Equity Research

Here is a sneak peek into how five technology stocks, MANH, MSCI, AEYE, HBIO and TXN, are expected to fare in their quarterly results slated to be released on Apr 23.

Harvard Bioscience (HBIO) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 2.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bruker (BRKR) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Bruker (BRKR) delivered earnings and revenue surprises of 4.17% and 5.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Momentum in Harvard Bioscience (HBIO) Should Keep going

by Zacks Equity Research

Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Aniruddha Ganguly headshot

3 Instruments Stocks to Watch From a Prospering Industry

by Aniruddha Ganguly

The Zacks Instruments - Scientific industry participants like Harvard Bioscience (HBIO), Mettler-Toledo (MTD) and Waters (WAT) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.

Here's What Could Help Harvard Bioscience (HBIO) Maintain Its Recent Price Strength

by Zacks Equity Research

Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Sweta Killa headshot

5 High-Flying Tech Stocks With Solid Growth Potential

by Sweta Killa

Investors should consider stocks like Harvard Bioscience (HBIO), MicroStrategy (MSTR), Meta Platforms (META), InterDigital (IDCC), and Weave Communications (WEAV) in their portfolio if they want to outperform the broader market.

What Makes Harvard Bioscience (HBIO) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Harvard Bioscience (HBIO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -120% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bruker (BRKR) Meets Q2 Earnings Estimates

by Zacks Equity Research

Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Harvard Bioscience (HBIO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Harvard Bioscience (HBIO) stock based on the movements in the options market lately.

Harvard Bioscience (HBIO) Loses 35.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Harvard Bioscience (HBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Harvard Bioscience (HBIO) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

PerkinElmer (PKI) delivered earnings and revenue surprises of 15.87% and 6.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Q3 Earnings Meet Estimates

by Zacks Equity Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harvard Bioscience (HBIO) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 20.00% and 6.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Reports Next Week: What to Know Ahead of the Release

by Zacks Equity Research

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are You Looking for a Top Momentum Pick? Why Harvard Bioscience (HBIO) is a Great Choice

by Zacks Equity Research

Does Harvard Bioscience (HBIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Harvard Bioscience (HBIO) Is a Great Choice for "Trend" Investors, Here's Why

by Zacks Equity Research

Harvard Bioscience (HBIO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Nitish Marwah headshot

4 Breakout Stocks You Must Add Right Away to Your Portfolio

by Nitish Marwah

The logic behind this strategy for stock selection is to identify stocks that are trading within a narrow band.

Sejuti Banerjea headshot

5 Stocks with Solid Track Records at Attractive Prices

by Sejuti Banerjea

This is probably the time to focus on fundamentals because we don't want to overpay for stocks in a buoyant market.

Surging Earnings Estimates Signal Upside for Harvard Bioscience (HBIO) Stock

by Zacks Equity Research

Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Harvard Bioscience (HBIO) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Harvard Bioscience (HBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Harvard Bioscience (HBIO) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 66.67% and 6.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?